Evotec (XTRA:EVT) Stock Faces Deeper EBITDA Losses After Guidance CutSimplywall·Aug 13 at 10:34 PMEVO+3.66%EVT
EVT: Revenue and profitability declined sharply, with losses deepening and guidance lowered for 2026Quartr·Aug 13 at 12:51 AMEVO+3.66%EVT
Evotec H1 FY26 adjusted EBITDA loss widens to EUR 42.7 million; revenue drops 19.2% to EUR 300.1 millionPUBT·Aug 13 at 12:28 AMEVO+3.66%EVT
Odyssey Therapeutics (ODTX) Stock Looks Reasonable As AI Research News LandsSimplywall·Aug 9 at 02:30 PMODTX+10.48%EVO+3.66%
Evotec and Odyssey collaborate on AI-enabled R&DPharmaceutical Technology·Aug 7 at 04:10 AMODTX+10.48%EVO+3.66%
Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases | EVO Stock NewsStockTitan·Aug 5 at 05:16 PMODTX+10.48%EVO+3.66%
Evotec publishes company presentation outlining drug discovery strategy and outlookPUBT·Aug 4 at 11:20 AMEVO+3.66%EVT
Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168 | EVO Stock NewsStockTitan·Aug 2 at 11:32 PMNAGE+3.59%EVO+3.66%
JPMorgan Chase raises Evotec voting rights stake to 5.09% from 4.97%PUBT·Jul 28 at 06:54 AMEVO+3.66%EVT
Evotec selects Navan to unify global travel and expense managementPUBT·Jul 23 at 02:01 AMEVO+3.66%NAVN-0.07%
